Back to today’s briefing

Story perspectives

Novo Nordisk Stock Plummets After CagriSema Trial Setback

2/23/2026

31 7 Full Breakdown

Summary

Story summary

Novo Nordisk's CagriSema failed to outperform Eli Lilly's tirzepatide in a trial, with 23% weight loss vs 25.5%.
Novo's stock fell 15% on the news, its lowest since June 2021.
Analysts say the treatment's market viability is uncertain after it missed its primary endpoint of non-inferiority.
CEO Mike Doustdar remains optimistic and plans higher-dose combination trials.
The FDA is expected to decide on CagriSema by late 2026.

1 of 1

Story summary

Novo Nordisk's CagriSema failed to outperform Eli Lilly's tirzepatide in a trial, with 23% weight loss vs 25.5%.
Novo's stock fell 15% on the news, its lowest since June 2021.
Analysts say the treatment's market viability is uncertain after it missed its primary endpoint of non-inferiority.
CEO Mike Doustdar remains optimistic and plans higher-dose combination trials.
The FDA is expected to decide on CagriSema by late 2026.